Suzhou Zelgen Biopharmaceutical

Zelgen is a leading Chinese biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in the fields of oncology, hematology, and liver diseases. The company has successfully launched its flagship product, Donafenib (Zepaton), a multi-kinase inhibitor approved for the treatment of advanced hepatocellular carcinoma and thyroid cancer. Zelgen's robust pipeline features several late-stage candidates, including Jaktinib, a JAK inhibitor targeting myelofibrosis and autoimmune conditions, and a recombinant human thrombin for surgical hemostasis. Utilizing its integrated R&D platforms for small molecules and recombinant proteins, the company maintains a comprehensive end-to-end capability from drug discovery to large-scale GMP manufacturing. Zelgen is publicly listed on the Shanghai Stock Exchange and continues to expand its footprint through global clinical trials and strategic partnerships.